C
제테마
216080KOSDAQ46.0 / 100
Reference Date: 2026-10-23
Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure14.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 15.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Jetema develops and manufactures biopharmaceuticals based on hyaluronic acid fillers and botulinum toxin, as well as tissue sutures and lifting threads, expanding into both aesthetic and therapeutic markets. Key products like Jetema Dermal Toxin, which received domestic approval in 2024, are driving growth, with global expansion accelerated through licensing agreements with partners in Brazil, China, and Thailand.
Number of Employees
244people
Average Salary
4.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.41Industry Average 1.200.0Point
2.8x industry avg (risky)
ROE
-10.91Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
92.88Industry Average 100.004.0Point
In line with industry avg
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲14.5% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲24.5% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 2.1% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (27%)
Current 5,950Won52-week high 10,89052-week low 4,050
1-month return1.0Point
1m -15.00% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
9 totalPositive 2Neutral 7Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-21
- Positive단일판매ㆍ공급계약체결2026-10-15
- Positive단일판매ㆍ공급계약체결2026-10-15
- Neutral주식등의대량보유상황보고서(일반)2026-10-12
- Neutral주식등의대량보유상황보고서(일반)2026-09-30